Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Surv
The participants are being asked to take part in this trial, because the participant is a survivor of childhood cancer or agreed to be part of a volunteer group to understand the relation between cancer and cancer treatment and muscle weakness in survivors of Acute Lymphoblastic Leukemia (ALL). ALL is cancer of the blo
| Condition(s) | Childhood Cancer, Muscle Weakness |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The participants are being asked to take part in this trial, because the participant is a survivor of childhood cancer or agreed to be part of a volunteer group to understand the relation between cancer and cancer treatment and muscle weakness in survivors of Acute Lymphoblastic Leukemia (ALL). ALL is cancer of the blood and bone marrow. Primary Objective • To compare muscle mtOXPHOS activity and satellite cell content among ALL survivors and controls. Secondary Objective * To evaluate the association between muscle mtOXPHOS, muscle satellite cell content and physical performance in ALL survivors. * To evaluate the association of muscle morphology and epigenetics with muscle mtOXPHOS in ALL survivors. |
| Who can participate | Inclusion Criteria: * Survivor- or Control-Participant is age 18 years old or older at time of consent and enrolled in SJLIFE. * Survivor- Participant is childhood ALL survivor * Survivor- or Control Participant has low muscle mass as defined by relative lean mass z-score of less than or equal to -0.5 SD (lean mass divided by height in meters squared). * Survivor - Participant is able and willing to give informed consent Exclusion Criteria: * Survivor-Participant has history of cranial radiation. * Survivor- or Control-Participant has implanted medical devices or metal that would interfere with MRI or MRS * Female Survivor- or Control-Participant is pregnant. * Survivor- or Control-Participant is taking anticoagulants (e.g. aspirin, apixaban, coumadin, edoxaban, rivaroxaban) * Survivor- or |
| Ages | 18 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | St. Jude Children's Research Hospital |
| Locations | Memphis, Tennessee, United States |
| Start date | 2025-06-02 |
| NCT ID | NCT06819475 |
| Official listing | https://clinicaltrials.gov/study/NCT06819475 |